Prostate cancer patients seek out mind-body care
Marcia Prenguber, ND, FABNO, director of integrative care at Goshen Center for Cancer Care in Indiana, said more than 75% of patients use complementary and alternative medicine, yet remain reluctant to tell their oncologists about it. Dr. Prenguber said she does not consider complementary medicine as an alternative to standard treatment, but as a way to tailor healing to the individual.
Marcia Prenguber, ND, FABNO, director of integrative care at Goshen Center for Cancer Care in Indiana, said more than 75% of patients use complementary and alternative medicine, yet remain reluctant to tell their oncologists about it. Dr. Prenguber said she does not consider complementary medicine as an alternative to standard treatment, but as a way to tailor healing to the individual.
“We combine conventional treatments with complementary care to determine what’s best for patients,” she said. “The relationship among providers and with patients ensures that the whole person, not just his prostate, is the center of care.”
J. Craig Gordon, BSN, is the prostate care coordinator at Waukesha Memorial Hospital in Wisconsin. He leads support groups once a month so that patients have continued access to assistance in between physician appointments and also offers one-on-one counseling. “I help patients navigate the system-from diagnosis all the way through long-term follow up,” he said.
The purpose of these meetings is to review pros and cons of treatment options, assess patient stress level, and offer coping mechanisms, Mr. Gordon explained.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
